Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective
Srujitha Marupuru, Daniel Arku, David R. Axon, Lorenzo Villa-Zapata, Mohsen Yaghoubi, Marion K. Slack, Terri Warholak
Dive into the research topics of 'Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective'. Together they form a unique fingerprint.